OptiBiotix secures 10 year presence of its LPLDL in Italy

OptiBiotix Health, a producer of obesity tackling products, and high cholesterol, diabetes and skin care, has ensured its cholesterol and blood pressure reducing LPLDL strain being sold in Italy for next 10 years, as it made an exclusive deal with Italian company ALFASIGMA S.p.A, an integrated multinational pharmaceutical company with revenues in 2017 exceeding €1 billion.

The 10 year license agreement will bring OptiBiotix an upfront payment and royalties with five figure guaranteed annual minimum payments, the company said. According to the press release by OptiBiotix, the agreement says ALFASIGMA will obtain the license to promote food supplements containing LPLDL throughout Italy for cardiovascular health, with the aim of maximising the financial return for both parties.

Outside of its core Italian market, ALFASIGMA has 16 subsidiaries in Europe, Asia, North & Central America and Africa, and has authorised distributors in more than 70 countries. More than 44% of ALFASIGMA turnover comes from internally developed proprietary products. One of these, Normix/Xifaxan, has reached a worldwide turnover in excess of €1.3 billion through ALFASIGMA partners, OptiBiotix said.

As highlighted in the OptiBiotix’s press release, this agreement follows on from the launch of LPLDL in the USA and is a strategic step to access high value high growth markets around the world. It extends the commercialisation of LPLDL into Italy, the largest probiotic supplement market in Europe, and the second largest market in the world. Italy is an estimated $500 million plus probiotic supplements market with a 25% yearly growth forecast to 2021, OptiBiotix said.

Per Rehne, Commercial Director of OptiBiotix, said that the 10 year exclusive agreement with ALFASIGMA which expands sales of LPLDL into Italy, the largest and fastest growing probiotic market in Europe, brings excitement. “ALFASIGMA are one of the largest pharmaceutical companies in Italy with a strong track record in food supplements and pharmaceuticals for cardiovascular health. This agreement provides upfront and guaranteed minimum future payments with LPLDL® offered in multiple product solutions to consumers in Italy. This agreement is another deal from a very strong pipeline with industry partners of increasing size and revenue potential targeted at the largest and fastest growing markets around the world,” Rehne said.